 |
|
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
A Meta-analysis
Catherine Delbaldo, MD;
Stefan Michiels, MSc;
Nathalie Syz, MSc;
Jean-Charles Soria, MD, PhD;
Thierry Le Chevalier, MD;
Jean-Pierre Pignon, MD, PhD
JAMA. 2004;292:470-484.
Context Randomized trials have demonstrated that adding a drug to a single-agent or to a 2-agent regimen increased the tumor response rate in patients with advanced non–small-cell lung cancer (NSCLC), although its impact on survival remains controversial.
Objective To evaluate the clinical benefit of adding a drug to a single-agent or 2-agent chemotherapy regimen in terms of tumor response rate, survival, and toxicity in patients with advanced NSCLC.
Data Sources and Study Selection Data from all randomized controlled trials performed between 1980 and 2001 (published between January 1980 and October 2003) comparing a doublet regimen with a single-agent regimen or comparing a triplet regimen with a doublet regimen in patients with advanced NSCLC. There were no language restrictions. Searches of MEDLINE and EMBASE were performed using the search terms non–small-cell lung carcinoma/drug therapy, adenocarcinoma, large-cell carcinoma, squamous-cell carcinoma, lung, neoplasms, clinical trial phase III, and randomized trial. Manual searches were also performed to find conference proceedings published between January 1982 and October 2003.
Data Extraction Two independent investigators reviewed the publications and extracted the data. Pooled odds ratios (ORs) for the objective tumor response rate, 1-year survival rate, and toxicity rate were calculated using the fixed-effect model. Pooled median ratios (MRs) for median survival also were calculated using the fixed-effect model. ORs and MRs lower than unity (<1.0) indicate a benefit of a doublet regimen compared with a single-agent regimen (or a triplet regimen compared with a doublet regimen).
Data Synthesis Sixty-five trials (13 601 patients) were eligible. In the trials comparing a doublet regimen with a single-agent regimen, a significant increase was observed in tumor response (OR, 0.42; 95% confidence interval [CI], 0.37-0.47; P<.001) and 1-year survival (OR, 0.80; 95% CI, 0.70-0.91; P<.001) in favor of the doublet regimen. The median survival ratio was 0.83 (95% CI, 0.79-0.89; P<.001). An increase also was observed in the tumor response rate (OR, 0.66; 95% CI, 0.58-0.75; P<.001) in favor of the triplet regimen, but not for 1-year survival (OR, 1.01; 95% CI, 0.85-1.21; P = .88). The median survival ratio was 1.00 (95% CI, 0.94-1.06; P = .97).
Conclusion Adding a second drug improved tumor response and survival rate. Adding a third drug had a weaker effect on tumor response and no effect on survival.
Author Affiliations: Departments of Medecine (Drs Delbaldo, Soria, Le Chevalier) and Biostatistics and Epidemiology (Mr Michiels, Ms Syz, and Dr Pignon), Institut Gustave-Roussy, Villejuif Cedex, France.
RELATED ARTICLE
Can Current Treatments for Advanced Non–Small-Cell Lung Cancer Be Improved?
Athanassios Argiris and Joan H. Schiller
JAMA. 2004;292(4):499-500.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evaluation of Trends in the Cost of Initial Cancer Treatment
Warren et al.
JNCI J Natl Cancer Inst 2008;100:888-897.
ABSTRACT
| FULL TEXT
Duration of First-Line Chemotherapy in Advanced Non Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent Therapies
Socinski and Stinchcombe
JCO 2007;25:5155-5157.
FULL TEXT
Treatment of Non-small Cell Lung Cancer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Socinski et al.
Chest 2007;132:277S-289S.
ABSTRACT
| FULL TEXT
Optimizing Combination Chemotherapy by Controlling Drug Ratios
Mayer and Janoff
Mol. Interv. 2007;7:216-223.
ABSTRACT
| FULL TEXT
Vascular Endothelial Growth Factor Trap in Non Small Cell Lung Cancer
Riely and Miller
Clin. Cancer Res. 2007;13:4623s-4627s.
ABSTRACT
| FULL TEXT
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
Sculier et al.
Ann Oncol 2007;18:1037-1042.
ABSTRACT
| FULL TEXT
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
Gatzemeier et al.
JCO 2007;25:1545-1552.
ABSTRACT
| FULL TEXT
Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature
Grossi et al.
The Oncologist 2007;12:451-464.
ABSTRACT
| FULL TEXT
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
Comella et al.
Ann Oncol 2007;18:324-330.
ABSTRACT
| FULL TEXT
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients
Auperin et al.
Ann Oncol 2006;17:473-483.
ABSTRACT
| FULL TEXT
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non-Small-Cell Lung Cancer: Results of a Phase II-III Study
Paccagnella et al.
JCO 2006;24:681-687.
ABSTRACT
| FULL TEXT
Astragalus-Based Chinese Herbs and Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Trials
McCulloch et al.
JCO 2006;24:419-430.
ABSTRACT
| FULL TEXT
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
Belani et al.
Ann Oncol 2005;16:1069-1075.
ABSTRACT
| FULL TEXT
Can Current Treatments for Advanced Non-Small-Cell Lung Cancer Be Improved?
Argiris and Schiller
JAMA 2004;292:499-500.
FULL TEXT
|
